Abstract
Pseudomonas aeruginosa — is one of the pathogens characterized by the critical number of multidrug-resistant (MDR) strains. Phage therapy is considered an alternative to antibiotics, especially in treatment of infections caused by MDR strains. The aim of this study was to isolate and characterize P. aeruginosa phages that could potentially be suitable for treating infectious diseases. To isolate the P. aeruginosa phages, enrichment cultures were used. The lytic activity spectrum was confirmed by spot testing on 40 P. aeruginosa strains. Whole-genome sequencing was performed using Illumina MiSeq instrument. Phylogenetic analysis was done using VICTOR tool. Isolated phages vB_PaeA-55-1w and vB_PaeM-198 from Autographiviridae and Myoviridae families, respectively, had a broad spectrum of lytic activity (about 50% each), including lysis of MDR strains. The genomes vB_PaeA-55-1w and vB_PaeM-198 comprise double-stranded DNA of 42.5 and 66.3 kbp in length, respectively. Open reading frames were annotated for both phages (52 for vB_PaeA-55-1w, and 95 for vB_PaeM-198), no integrases and toxins were detected. On a phylogenetic tree, vB_PaeA-55-1w phage was clustered with phages from the Phikmvvirus genus (Autographiviridae family), which are also used in phage therapy. vB_PaeM-198 phage was clustered with phages from the Pbunavirus genus (Myoviridae family). vB_PaeA-55-1w and vB_PaeM-198 phages could be considered as candidates for phage therapy and may be used to treat infections caused by MDR P. aeruginosa.
Highlights
Kornienko MA, Kuptsov NS, Danilov DI, Gorodnichev RB, Malakhova MV, Bespiatykh DA, Veselovsky VA, Shitikov EA, Ilina EN Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency, Moscow, Russia
There are several commercial therapeutic drugs designed to counter infections caused by P. aeruginosa that are produced in Russia: Pseudomonas aeruginosa bacteriophage, Intesti-bacteriophage, Polyvalent purified pyobacteriophage (Microgen; Russia)
Detailed characterization of the studied bacteriophages relied on the whole genome sequencing data and annotation thereof
Summary
Kornienko MA , Kuptsov NS, Danilov DI, Gorodnichev RB, Malakhova MV, Bespiatykh DA, Veselovsky VA, Shitikov EA, Ilina EN Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency, Moscow, Russia. Выделенные бактериофаги vB_PaeA-55-1w и vB_PaeM-198, принадлежащие к семействам Autographiviridae и Myoviridae соответственно, обладали широким спектром литической активности (около 50% каждый), в том числе вызывали лизис штаммов с МЛУ. Бактериофаги vB_PaeA-55-1w и vB_PaeM-198 можно рассматривать в качестве кандидатов для применения в фаготерапии, в том числе и для лечения инфекций, вызванных штаммами P. aeruginosa с МЛУ. Ключевые слова: Pseudomonas aeruginosa, вирулентные бактериофаги, фаготерапия, Autographiviridae, Myoviridae, полногеномное секвенирование, филогенетический анализ Финансирование: исследование выполнено за счет средств, предоставленных для выполнения государственного задания «Разработка персонализированного подхода терапии инфекционных процессов с применением вирулентных бактериофагов» (ШИФР: Бактериофаг). Gram-negative bacteria, including Pseudomonas aeruginosa, occupy the first places in the global priority list of antibioticresistant bacteria posing the greatest threat to human health [1] The bacteria of this species are ubiquitous, their genetic plasticity and environmental adaptability are high. There are several commercial therapeutic drugs designed to counter infections caused by P. aeruginosa that are produced in Russia: Pseudomonas aeruginosa bacteriophage, Intesti-bacteriophage, Polyvalent purified pyobacteriophage (Microgen; Russia)
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
